








Wednesday, February 3 | 18:00–19:00 (CET)

Advancing prophylaxis in times of uncertainty: From rFVIII to gene therapy

Hear our expert panel discuss the complexity of the current treatment landscape during these unprecedented times. They will explore the data being collected on the impact of COVID-19 on patients with hemophilia A, describe how advances in rFVIII design can benefit patients, and share the key considerations for the design of gene therapies.

Time	Session title	Speaker
10 min	 Hemophilia A during the COVID-19 pandemic: Study results from the ADVANCE group	Catherine Lambert (Chair)
20 min	 Empowering individualization: H2H PK and rFVIII long-term efficacy data	Maria Elisa Mancuso
10 min	 rFVIII in real-world clinics: Update from the Bonn Center	Natascha Marquardt
10 min	 Acting now with tomorrow in mind: The latest on Bayer's gene therapy	Steven Pipe
10 min	 Q&A	All

H2H, head-to-head; PK, pharmacokinetic; rFVIII, recombinant factor VIII.

BAYER and the Bayer Cross are registered trademarks of Bayer. All other trademarks are property of their respective owners.

This symposium is organized and sponsored by Bayer. EAHAD 2021 is an international virtual congress run by EAHAD and provided to international HCPs from around the world.

© 2021 Bayer AG. All rights reserved.

Bayer Consumer Care AG, Peter Merian-Straße 84, 4052 Basel, Switzerland.

January 2021 | PP-GENE-ALL-0004-1